Narrowed label for Biogen’s Aduhelm lays bare FDA’s fail
In an unprecedented situation Biogen sought to restrict the use of Aduhelm weeks after the drug’s approval. And the FDA said yes.
Asco 2021 – Bristol makes more progress in stomach cancer
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Asco 2021 – full Olympia results sweep away Parp doubts
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
